Gilead Announces Executive Promotions

Gilead Sciences, Inc. (Nasdaq:GILD) today announced the promotion of William Lee, PhD to Executive Vice President, Research, and Brett Pletcher to Executive Vice President and General Counsel. Dr. Lee and Mr. Pletcher will both join Gilead’s senior leadership committee.

Dr. Lee joined Gilead in 1991 and was promoted to Senior Vice President, Research in 2000. He has led the expansion of the company’s research activities across a range of therapeutic areas, including HIV, liver diseases, hematology/oncology, inflammation and respiratory diseases and cardiovascular conditions. He reports to Norbert Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer. Prior to joining Gilead, Dr. Lee worked at California Biotechnology, Inc. and Syntex. He received his BS in Chemistry from the University of Massachusetts, PhD in Chemistry from the University of California at San Diego and did postdoctoral work at the Ecole Polytech Federal Lausanne and the University of California at Santa Barbara.

“Over the past nearly 25 years, Bill has helped Gilead bring multiple product candidates from early stage research into development. His contributions to the discovery and advancement of internal drug candidates and evaluation of external candidates for potential partnership have allowed Gilead to bring important new medicines to patients around the world,” commented Dr. Bischofberger.

Mr. Pletcher joined Gilead in 2005 and most recently served as Senior Vice President and General Counsel. With this promotion, Mr. Pletcher also becomes corporate Secretary for the company. He reports to Gregg Alton, Executive Vice President, Corporate and Medical Affairs. Prior to joining Gilead, Mr. Pletcher was a partner in the law firm of Gunderson Dettmer, LLP, where he focused on providing corporate and securities services to emerging growth public and private companies and venture capital investors. He received his bachelor’s degree in economics and political science from the University of California, Riverside and his law degree from the University of California, Berkeley’s Boalt Hall School of Law. He is a member of the California State Bar and the Nasdaq Listing and Hearing Review Council.

“Brett’s leadership has been instrumental in helping Gilead manage a period of significant growth and complexity, particularly as we introduce medicines in new geographies. His expertise has helped Gilead protect its intellectual property around the world and ensure compliance across countries with vastly different legal systems,” commented Mr. Alton.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company’s website at www.Gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150727006228/en/

Contact information

Gilead Sciences, Inc.
Investors:
Patrick O’Brien, 650-522-1936
Media
Amy Flood, 650-522-5643